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Oxidative stress is considered a causative factor in carcinogenesis, but also in the development of re-
sistance to current chemotherapies. The appropriate usage of redox-modulating compounds is limited by
the lack of knowledge of their impact on speciﬁc molecular pathways. Increased levels of the IKKε kinase,
as a result of gene ampliﬁcation or aberrant expression, are observed in a substantial number of breast
carcinomas. IKKε not only plays a key role in cell transformation and invasiveness, but also in the de-
velopment of resistance to tamoxifen. Here, we studied the effect of in vitro treatment with the redox-
modulating triphenylmethane dyes, Gentian Violet and Brilliant Green, and nitroxide Tempol on IKKε
expression and cell proliferation in the human breast cancer epithelial cell lines exhibiting ampliﬁcation
of IKKε, MCF-7 and ZR75.1. We show that Gentian Violet, Brilliant Green and Tempol signiﬁcantly de-
crease intracellular superoxide anion levels and inhibit IKKε expression and cell viability. Treatment with
Gentian Violet and Brilliant Green was associated with a reduced cyclin D1 expression and activation of
caspase 3 and/or 7. Tempol decreased cyclin D1 expression in both cell lines, while activation of caspase
7 was only observed in MCF-7 cells. Silencing of the superoxide-generating NOX2 NADPH oxidase ex-
pressed in breast cancer cells resulted in the signiﬁcant reduction of IKKε expression. Taken together, our
results suggest that redox-modulating compounds targeting NOX2 could present a particular therapeutic
interest in combination therapy against breast carcinomas exhibiting IKKε ampliﬁcation.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Breast cancer is a leading cause of cancer-related mortality in
women, second only to lung cancer. Breast carcinomas are char-
acterized by their biological complexity and heterogeneity. Initia-
tion and progression of breast cancer is a multi-step process that
involves the dysregulation of multiple genes controlling cell sur-
vival and proliferation [1,2]. IKKε (also known as IKBKE or IKKi) is
part of the IKK family of kinases, of which IKKα and IKKβ are the
classical members, well known for their role in the activation of
the NF-κB transcription factor [3,4]. Increased IKKε activity, as aB.V. This is an open access article u
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treal.ca (R. Lapointe),result of ampliﬁcation of the 1q32 region comprising the IKBKE
locus and/or aberrant expression, was identiﬁed in 30% primary
breast tumors, in epithelial breast cancer cell lines and in murine
mammary breast tumors induced by 7,12-dimethylbenzene(a)an-
thracene (DMBA) [5,6]. Functional studies have shown that IKKε
plays a key role in cell transformation and invasiveness [6–8].
IKKε-mediated mammary epithelial cell transformation is depen-
dent on the phosphorylation of the cylindromatosis tumor sup-
pressor (CYLD), the estrogen receptor α (ERα), the tumor necrosis
factor receptor-associated factor 2 (TRAF2) E3 ligase and of the
Forkhead box O 3a (FOXO3a) transcription factor [8–11]. Expres-
sion of the CCND1 (Cyclin D1), MMP-9 (metalloproteinase-9) and
Bcl-2 genes was found to be dependent on IKKε activity [5,6,9].
Importantly, IKKε was also shown to contribute to the develop-
ment of resistance of hormone-dependent breast cancers to the
selective estrogen receptor modulator tamoxifen, likely through its
role in ERα phosphorylation [9]. Primary or acquired resistance to
tamoxifen severely reduces its clinical effectiveness andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Cellular redox homeostasis, fundamental for a proper function
of the cell, results from a critical balance between production of
reactive oxygen species (ROS) and detoxiﬁcation ensured by anti-
oxidant enzymes. ROS control various cell responses, ranging from
proliferation, motility, senescence, severe cellular damage and cell
death, in a cell-type and dose-dependent manner [13–17]. In
cancer cells high ROS production/antioxidant capacity results in
high ROS levels that are yet compatible with cell survival [18].
Oxidative stress has emerged as an important pathogenic factor in
the development of a large number of tumors and malignant cells,
including breast carcinomas [17,19,20]. Traditionally, the oxidative
stress theory of cancer is associated with the capacity of ROS to
induce DNA damage and promote genetic instability. However,
ROS are now well appreciated to act as cellular switches for sig-
naling cascades [21,22]. Intriguingly, ROS are double-edged swords
that can have dual roles in cancer by either promoting proonco-
genic or antitumorigenic signaling pathways, making the use of
redox-modulating agents in anticancer therapeutic strategies a
complex task [18,23]. Conversion of breast tumors to a Tam-re-
sistant phenotype was also reported to be associated with oxida-
tive stress [24–26].
A major hurdle in the use of most compounds with known
redox-modulating activities is the lack of knowledge of their im-
pact on speciﬁc molecular pathways. Thus, a better understanding
of the pathways that are altered by redox-modulating compounds
in breast cancer cells will help deﬁne an appropriate therapeutic
usage. Here, we studied the impact of the cationic triphe-
nylmethane dyes, Brilliant Green and Gentian Violet, on ERαþ
breast cancer epithelial cell lines, MCF-7 and ZR75.1, which exhibit
cell growth dependence on ampliﬁed IKKε [27]. Brilliant Green
and the Federal Drug Administration (FDA)-approved Gentian
Violet are of particular interest as they have a long history of hu-
man and veterinary use in many conditions including bacterial,
fungal and parasitic infections [28,29]. Gentian Violet and Brilliant
Green were recently shown to have an impact on host cells with
an effect on cellular redox mechanisms by inhibition of NADPH
oxidases [30] and modulation of the thioredoxin (Trx) system [31].
The observation that Gentian Violet and Brilliant Green inhibit
NADPH oxidases has expanded their use to treatment of cutaneous
melanoma metastasis and hemangiomas [30,32]. We also studied
the impact of a different class of redox-modulating agent using the
nitroxide Tempol, 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-
oxyl, a cell-permeant superoxide dismutase mimetic that is the
lead compounds of a series of nitroxide that have antioxidant ac-
tivities, mainly through free radical scavenging [33,34].
Here, we show that Gentian Violet, Brilliant Green and Tempol,
which all signiﬁcantly decreased intracellular superoxide levels,
impaired the expression of the oncogenic IKKε kinase in MCF-7
and ZR75.1 cells. We also report that either treatment signiﬁcantly
reduced cell viability. Treatment with Gentian Violet and Brilliant
Green was associated with a reduced cyclin D1 expression and
activation of caspase 3 and/or 7. Tempol decreased cyclin D1 ex-
pression in both cell lines, but activation of caspase 7 was only
observed in MCF-7 cells, but not in ZR75.1 cells. Distinct isoforms
of the NADPH oxidases family (NOX1-5/DUOX1-2) were found
expressed in MCF-7 and ZR75.1 cells and in primary breast tumors.
Knockdown of the superoxide-generating NOX2 isoform resulted
in signiﬁcant reduction of IKKε expression. Taken together, our
data show that the molecular consequences of the treatment of
breast cancer cells exhibiting ampliﬁcation of the IKKε kinase with
Gentian Violet and Brilliant Green, or Tempol involve the inhibi-
tion of NOX2-dependent IKKε expression and an antiproliferative
response. These ﬁndings provide valuable insights into the use of
redox-modulating agents that target at least NOX2 in the treat-
ment of breast cancers highly expressing IKKε kinase.2. Methods
2.1. Reagents
Gentian Violet and Brilliant Green were purchased from Sigma-
Aldrich. Tempol was from Enzo Life Sciences. Previously described
RNAi oligonucleotides (RNAi, [35]) and Dharmafect 1 transfection
reagent were from Dharmacon.
2.2. Cell culture
ZR75.1 and MCF-7 breast cancer cell lines were obtained from
Dr. S. Mader, Université de Montréal, Canada. ZR75.1 cells were
cultured in RPMI 1640 medium supplemented with 10% heat-in-
activated FBS (HI-FBS) and 1% L-glutamine. MCF-7 cells were
maintained in MEM medium supplemented with 10% HI-FBS, 1% L-
glutamine, 1% non-essential amino acids and 1% sodium pyruvate.
All media and supplements were obtained from Life Technologies.
All cultures were performed without antibiotics and controlled for
the absence of mycoplasma contamination on a regular basis using
the MycoAlert Mycoplasma Detection Kit (Lonza).
2.3. Primary breast tumor samples
Primary breast tumors samples were provided by the “Banque
de tissues et de données” of the “Réseau de Recherche sur le
cancer” of the Fonds de Recherche Du Quebec – Santé (FRQS),
which is afﬁliated with the Canadian tumor repository network.
Written and informed consent was obtained from each patient.
The present research was conducted with the approval of the
Ethics Committee of the CRCHUM where the experiments were
performed.
2.4. Transfection of RNAi oligonucleotides
Transfection of RNAi oligonucleotides was performed using the
Dharmafect1 transfection reagent according to the manufacturer’s
instructions. Cells were plated in 35 mm plates to reach 30–40%
conﬂuency at the time of transfection and were transfected using
8 ml of transfection reagent and 100 pmol of oligonucleotide.
Transfection was pursued for 72 h before harvesting.
2.5. Intracellular superoxide detection
Intracellular superoxide levels were assessed using the ﬂuor-
escent dye dihydroethidium (DHE, Life Technologies) by ﬂow cy-
tometry. MCF-7 and ZR75.1 were cultured and treated with the
indicated compounds in phenol-red free medium for 2–4 h. Cells
were loaded with 1 mM DHE for 1 h at 37 °C before being collected
by brief trypsinization. Cells were washed twice in PBS, and re-
suspended in HBSS for analysis using an LSR-II (BD Biosciences).
Cells were excited at 488 nm and emission was collected at
575 nm, which are speciﬁc for the detection of the superoxide-
speciﬁc DHE metabolite oxyethidium [36]. No dye cells (data not
shown) and vehicle-treated cells were used as controls. All data
were acquired with the FACSDiva (BD Biosciences) and analyzed
using the FlowJo software (BD Biosciences).
2.6. RT-PCR analyses
Total RNA from MCF-7 and ZR75.1 cells was prepared using the
RNAqueous-96 Isolation Kit (Ambion). Total RNA from primary
breast tumors was prepared as described in [37]. Total RNA was
subjected to reverse transcription using the QuantiTect Reverse
Transcription Kit (Qiagen). Quantitative PCR ampliﬁcations of IKKε,
NOX2, NOX5, S9 and β-actin genes were performed using the Fast
Fig. 1. IKKε expression levels in MCF-7 compared to ZR75.1 cells. (A) Total RNA were extracted from MCF-7 and ZR75.1 cells, subjected to reverse transcription and IKKε
mRNA expression was quantiﬁed by RT-qPCR and expressed as fold over MCF-7 level after normalization to actin expression. (B) WCE extracts were prepared and resolved by
SDS-PAGE. Immunoblot analyses were performed using anti-IKKε and anti-TBK1 antibodies. Anti-actin antibodies were used to control equal loading. Data are representative
of two experiments.
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Thermal Cycler (Corbett Research). Absence of genomic DNA
contamination was analyzed using a reaction without reverse
transcriptase. Gene expression normalized over actin or S9 was
analyzed using the ΔΔ Cycle threshold (Ct) method [38] or as
absolute mRNA copy numbers using plasmid-based standard
curves as described in [39]. RT-PCR analysis of NOX/DUOX iso-
forms expression was performed as previously described [35].
Positive controls were used for each gene, as follows: total RNA
from colon was used for NOX1; total RNA from DMSO-differ-
entiated HL60 was used for NOX2; total RNA from human fetal
kidney was used for NOX3; total RNA from MRC-5 were used for
NOX4; total RNA from human spleen was used for NOX5; total RNA
from human thyroid was used for DUOX1 and DUOX2. Human
thyroid total RNA, human fetal kidney total RNA, human colon
total RNA, and human spleen total RNA were purchased from BD
Clontech.
2.7. Quantiﬁcation of cell viability
Cell viability was monitored after the indicated time of treat-
ment with the pharmacological inhibitors or the corresponding
vehicle using a crystal violet colorimetric assay [40]. The optical
density (570 nm) was determined and expressed as a relative va-
lue in percent of control cells treated with the vehicle.
2.8. Immunoblot analysis
Whole cell extracts (WCE) were prepared in Nonidet P-40 lysis
buffer (50 mM Hepes pH 7.4, 150 mM NaCl, 5 mM EDTA, 10%
Glycerol, 1% IGEPALs CA-630 supplemented with 1 mg/ml leu-
peptin, 2 mg/ml aprotinin, 5 mM NaF, 1 mM orthovanadate, 2 mM
PNPP, 10 mM β-glycerophosphate pH 7.5) for 20 min on ice fol-
lowed by 3 rounds of freeze and thaw. WCE were collected after
centrifugation at 17,000g for 20 min at 4 °C. WCE were subjected
to SDS-PAGE electrophoresis and transferred onto nitrocellulose
membrane (Biorad). The membrane was blocked in PBS containing
0.5% Tween (PBS-T) and 5% nonfat dry milk for 1 h at room tem-
perature before incubation with the following primary antibodies:
anti-cleaved Caspase 3, anti-cleaved Caspase 7, anti-PARP, anti-
IKKε and anti-cyclin D1 (all from Cell Signaling), anti-TBK1 (Im-
genex) and anti-actin (Chemicon International). Antibodies were
diluted in PBS-T containing either 5% nonfat dry milk or BSA. After
5 washes in PBS-T, membranes were incubated for 1 h with HRP-
conjugated goat anti-rabbit (Kirkegaard & Perry Laboratories or
Jackson Immunoresearch Labs) or goat anti-mouse secondaryantibodies (Kirkegaard & Perry Laboratories) in blocking solution.
Immunoreactive bands were visualized by enhanced chemilumi-
nescence using the Western Lightning Chemiluminescence Re-
agent Plus (PerkinElmer Life Sciences) and detected using a
LAS4000mini CCD camera apparatus (GE Healthcare). Quantiﬁca-
tion was performed using the ImageJ v1.42q software.
2.9. Statistical analyses
Results are presented as the mean of a minimum of 3 in-
dependent replicates7standard deviation (SD) or standard de-
viation to the mean (SEM) as indicated. Statistical analyses were
performed with the GraphPad Prism software version 5.0 using
the indicated tests. Statistical relevance was evaluated using the
following p values: po0.05 (*), po0.01 (**) and po0.001 (***).3. Results
Tempol, Gentian Violet and Brilliant Green reduce intracellular
superoxide levels in MCF-7 and ZR75.1 breast cancer cell lines
exhibiting ampliﬁcation of IKKε.
A previous report showed that MCF-7 and ZR75.1 exhibit am-
pliﬁcation of the IKBKE gene encoding the IKKε kinase, reﬂecting a
similar observation made in a substantial fraction of primary
breast tumors [6]. Ten copies of IKBKE were detected in ZR75.1
cells and ﬁve copies in MCF-7 cells [6]. Here, we conﬁrmed that
ZR75.1 cells express higher IKKεmRNA (Fig. 1A) and protein levels
(Fig. 1B) than MCF-7 cells. In contrary, protein expression levels of
the closely related IKKε homolog Tank Binding Kinase 1 (TBK1)
was similar in the two cell lines (Fig. 1B).
MCF-7 and ZR75.1 cells were left untreated (control) or in-
dividually treated with the triphenylmethane dyes, Gentian Violet
and Brilliant Green, and the nitroxide Tempol before staining with
the dihydroethidium (DHE) ﬂuorescent probe and analysis by ﬂow
cytometry (ex: 488 nm/em: 575 nm). Consistent with a reduction
in superoxide levels, a signiﬁcant reduction in the median DHE
ﬂuorescence was observed in MCF-7 (Fig. 2A) and in ZR75.1 cells
(Fig. 2B) treated with 5 mM Gentian Violet or 5 mM Brilliant Green
compared to control cells. Treatment of MCF-7 cells with 5 mM
Tempol (Fig. 2A) and ZR75.1 cells with 3 mM Tempol (Fig. 2B) also
signiﬁcantly reduced the median DHE ﬂuorescence. These ob-
servations demonstrate that triphenylmethane dyes and nitroxide
Tempol signiﬁcantly reduce intracellular superoxide levels in
IKKε-expressing MCF-7 and ZR75.1 breast cancer cell lines.
Tempol and triphenylmethane dyes inhibit IKKε expression in
Fig. 2. Reduction of intracellular superoxide levels in cells treated with tempol, Gentian Violet or Brilliant Green. In (A), MCF-7 cells were left untreated or treated with
Tempol (T, 5 mM), Gentian Violet (GV, 5 mM) or Brilliant Green (BG, 5 mM). In (B), ZR75.1 cells were left untreated or treated with Tempol (3 mM), Gentian Violet (5 mM) or
Brilliant Green (5 mM). Intracellular superoxide levels were monitored using staining with the ﬂuorescent dye DHE. Fluorescence (ex: 488 nm/em: 575 nm) was acquired by
ﬂow cytometry and the median of ﬂuorescence was quantiﬁed. Values are means7SEM from nZ3. Statistical comparison (treated cells vs untreated cells) was performed
using a t-test.
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To determine if treatment of breast cancer cells with the redox-
modulating triphenylmethane dyes or Tempol modulates IKKε
expression levels, MCF-7 and ZR75.1 cells were subjected to
treatment with each of the compounds for 8–24 h and further
analyzed by immunoblot using anti-IKKε antibodies. As shown in
Fig. 3, Tempol, Gentian Violet and Brilliant Green decreased IKKε
expression with signiﬁcant inhibition at 5 mM, 10 and 5 mM, re-
spectively in MCF-7 cells (Fig. 3A–C) and at 3 mM, 5 and 5 mM,
respectively in ZR75.1 cells (Fig. 3D and E). Of note, in these same
conditions the expression levels of TBK1 remained steady (Fig. 3A
and D). The CCND1 gene, encoding cyclin D1, was previously
shown to be regulated by IKKε in epithelial breast cancer cells
[5,6,9]. Immunoblot analyses showed that cyclin D1 expression is
impaired by Gentian Violet, Brilliant Green or Tempol treatment in
MCF-7 and ZR75.1 cells with a proﬁle similar to that of IKKε ex-
pression (Fig. 4). Taken together, these results demonstrate that
Tempol, Gentian Violet and Brilliant Green signiﬁcantly impair
expression of the IKKε oncogenic kinase in breast cancer cells
exhibiting ampliﬁcation of the IKBKE gene.
Tempol and triphenylmethane dyes exhibit potent anti-pro-
liferative activity in MCF-7 and ZR75.1 cells.
We next evaluated the impact of Gentian Violet, Brilliant Green
and Tempol on breast cancer cells growth. MCF-7 and ZR75.1 were
treated with increasing concentrations of either compound for 8–
24 h (Fig. 5). Both cell lines exhibited a concentration-dependent
susceptibility to Tempol, Gentian Violet or Brilliant Green, albeit
with different sensitivities as evidenced by half-maximal in-
hibitory concentration (IC50) values measured at 24 h (Fig. 5B and
D). The IC50 values for Gentian Violet were 2.87 and 2.6 mM inMCF-7 and ZR75.1 cells, respectively. The IC50 value for Brilliant
Green was 1.28 mM in MCF-7 cells, while it was of 3.42 mM in
ZR75.1 cells. This revealed that Gentian Violet and Brilliant Green
were more potent inhibitors than Tempol, which exhibited sig-
niﬁcantly higher IC50 values of 2.8 mM in MCF-7 cells and 2.7 mM
in ZR75.1 cells. Collectively, these results highlight the potent an-
tiproliferative effect of Gentian Violet, Brilliant Green and Tempol
in breast cancer cells.
Distinct effect of Tempol and Triphenylmethane dyes on cas-
pase 3 and/or 7 activation in MCF-7 and ZR75.1.
To further document the molecular consequences of treatment
with Gentian Violet, Brilliant Green or Tempol, we next sought to
analyze caspase 3/7 activation through immunoblot detection of
the proapoptotic cleaved caspase 3 and 7, as well as the cleaved
caspase substrate PARP, in cells treated with Tempol, Gentian
Violet or Brilliant Green (Fig. 6). Caspase 3 cleavage was only as-
sessed in ZR75.1 cells as, as previously described, MCF-7 cells are
deﬁcient in caspase 3 [41]. Treatment of MCF-7 and ZR75.1 cells
with Gentian Violet or Brilliant Green led to a signiﬁcant induction
of cleaved caspase 7 and PARP (Fig. 6). Additionally, caspase
3 cleavage was detected in Gentian Violet- and Brilliant Green-
treated ZR75.1 cells (Fig. 6A). Treatment with Tempol resulted in
the cleavage of caspase 7 and PARP in MCF-7 cells, but neither
caspase 3, caspase 7 nor PARP cleavage was observed in ZR75.1
cells (Fig. 6). These results show that treatment of breast cancer
cells with the triphenylmethane dyes, Gentian Violet and Brilliant
Green, induces caspase 3/7 activation. Although Tempol induces
inhibition of IKKε expression and cell growth in MCF-7 and ZR75.1
cells, it induces caspase activation in MCF-7 cells, but not in ZR75.1
cells.
Fig. 3. Treatment with Gentian Violet, Brilliant Green or Tempol decreases oncogenic IKKε kinase expression levels. MCF-7 (A–C) and ZR75.1 (B–F) were left untreated or
treated with Tempol (T), Gentian Violet (GV) or Brilliant Green (BG) at the indicated concentrations for 24 h (A, C, D and F) or the indicated times (B and E). WCE were
resolved by SDS-PAGE and analyzed by immunoblot using anti-IKKε and anti-TBK1 antibodies. Equal loading was monitored using anti-actin antibodies. Representative
immunoblots of at least three experiments are shown. In (C) and (F), IKKε levels were quantiﬁed by densitometric analysis using the ImageJ software. Quantiﬁcation data are
expressed as mean7SEM from nZ3. Statistical comparison was performed using a t-test.
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The triphenylmethane dyes, Gentian Violet and Brilliant Green,
were recently shown to alter the redox cellular status through
inhibition of ROS-generating NADPH oxidase activities [42]. Ana-
lysis of NADPH oxidase isoforms, NOX1-5 and DUOX1-2, mRNA
expression in MCF-7 and ZR75.1 cells (Fig. 7A) and in primary
breast tumors (Fig. 7B) revealed the expression of distinct isoforms
of superoxide-generating NOX2 and NOX5 and hydrogen per-
oxide-generating NOX4 and DUOX1 [43]. According to the ob-
served modulation of intracellular superoxide levels following
treatment with Gentian Violet and Brilliant Green (Fig. 1), the role
of NOX2 and NOX5 was analyzed. NOX2 and/or NOX5 were
downregulated using RNAi in MCF-7 cells and expression of IKKε
and TBK1 were monitored by immunoblot. IKKε speciﬁc-RNAi was
used as a positive control. Silencing of NOX2, but not of NOX5,
resulted in the signiﬁcant inhibition of IKKε expression, while
TBK1 levels remained steady (Fig. 7C). Neither silencing of NOX2
nor silencing of IKKε was sufﬁcient to decrease cell viability
(Fig. 7D).
Altogether, our results show that treatment of breast cancer
cells exhibiting ampliﬁcation of the IKKε kinase with the redox
modulating triphenylmethane dyes, Gentian Violet and Brilliant
Green, and nitroxide Tempol leads to a signiﬁcant decrease in
NOX2-dependent IKKε expression.4. Discussion
Because oxidative stress is considered a causative factor in
carcinogenesis, including breast cancer, compounds with redox-
modulating activities have attracted much attention as potential
therapeutic agents [18,23]. Importantly, ROS have also been asso-
ciated with the development of resistance to tamoxifen treatment
[24–26]. Tamoxifen is the most widely selective estrogen receptor
modulator adjuvant used for the treatment of hormone-depen-
dent breast cancers, which allowed 40–50% decrease in the odds of
recurrence and reduced mortality by nearly a third [44]. However,
primary or acquired resistance to tamoxifen severely reduced its
clinical effectiveness, constituting a serious threat to the eradica-
tion of breast cancer [12]. Because persistent oxidative stress was
also shown to mediate anti-tumorigenic responses [18,23], a better
understanding of the pathways that are altered by compounds
used for their capacity to modulate the redox state of cancer cells
is required to move them toward appropriate clinical applications.
In the present study, we report that the triphenylmethane dyes,
Gentian Violet and Brilliant Green, and nitroxide Tempol, reduce
intracellular superoxide levels and exhibit potent growth inhibit-
ing activities of the breast cancer epithelial cell lines MCF-7 and
ZR75.1 that present different levels of IKBKE ampliﬁcation. Mole-
cular analyses revealed that the three compounds signiﬁcantly
diminished the expression of IKKε, an oncogenic kinase that is not
Fig. 4. Tempol, Gentian Violet and Brillant Green treatment impair cyclin D1 ex-
pression. MCF-7 (A) and ZR75.1 (B) were left untreated or treated for 24 h with
Tempol (T), Gentian Violet (GV) or Brilliant Green (BG) at the indicated con-
centrations. WCE were resolved by SDS-PAGE and analyzed by immunoblot using
anti-cyclin D1 and anti-actin antibodies. Experiments were performed three times.
Representative immunoblots are shown.
Fig. 5. Tempol, Gentian Violet and Brilliant Green signiﬁcantly decrease viability of MCF-
treated with Tempol (T), Gentian Violet (GV) or Brilliant Green (BG). In A and C, inhibit
various times by the crystal violet assay. In (B) and (D), cell viability was monitored after
curve ﬁt (log[inhibitor] vs normalized response) were obtained using GraphPad Prism s
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invasiveness [5–7,45,46], but also contributes to the development
of breast cancer cells resistance to tamoxifen treatment likely
through the phosphorylation of ERα [9]. Thus, our observation that
Gentian Violet, Brilliant Green and Tempol diminish IKKε expres-
sion in breast cancer cells encourages the investigation of combi-
nation anticancer therapies to limit the development of resistance
to tamoxifen. Aberrant expression of IKKε expression has also
been observed in prostate tumors [47] and is associated with poor
prognosis in ovarian cancer [48]. Therefore, impairment of IKKε
expression by redox-modulating agents might also be of interest
for the treatment of ovarian and prostate cancers.
Gentian Violet and Brilliant Green were shown to be potent and
efﬁcacious inhibitors of ROS-generating NOX2 and NOX4 activities
[30]. The role of NADPH oxidases in breast tumor initiation and
progression appears to be complex, as different isoforms of NADPH
oxidase, NOX1, NOX2 and NOX4, have previously been shown to be
involved in ROS production in epithelial breast cancer cells and
contribute to cell proliferation, through induction of pro-survival
pathways, regulation of cellular senescence, resistance to apopto-
sis, and tumorigenic transformation [49–53]. Brilliant Green at
nanomolar concentrations was also shown to induce mitochon-
drial Trx2 oxidation and degradation in HeLa cells and ﬁbroblasts
[31]. Assessment of NADPH oxidases (NOX1-5/DUOX1-2) expres-
sion in MCF-7 and ZR75.1 cells and in 10 primary breast tumor
samples conﬁrmed the expression of distinct isoforms of NADPH
oxidases. Of note, NOX2, NOX4 and NOX5 were detected in cell
lines and primary tumors, while DUOX1 expression was not de-
tected in MCF-7 and ZR75.1 cells. The observation that NOX2 si-
lencing signiﬁcantly impaired IKKε expression in MCF-7 cells,
strongly supports that Gentian Violet and Brilliant Green regulate
IKKε expression, at least in part, through their ability to inhibit
NOX2. The Trx system is one of the major components of the thiol7 and ZR75.1 cells. MCF-7 (A and B) and ZR75.1 (C and D) cells were left untreated or
ors were used at the indicated concentrations and cell viability was determined at
treatment with increasing concentrations of either inhibitor. Non-linear regression
oftware. Plotted data correspond to the mean7SD (nZ3).
Fig. 6. Cell-type speciﬁc activation of caspases by Tempol, Gentian Violet and Brillant Green. MCF-7 (A) and ZR75.1 (B) were treated with the indicated concentration of
Tempol (T), Gentian Violet (GV) or Brilliant Green (BG) for 24 h. WCE were analyzed by immunoblot for cleaved-caspase 3 (19 and 17 kDa), cleaved-caspase 7 (20 kDa) and
PARP (Full-length 116 kDa and cleaved 89 kDa). Equal loading was monitored using anti-actin antibodies. Representative immunoblots of three different experiments are
shown.
E. Mukawera et al. / Redox Biology 6 (2015) 9–18 15reducing system that plays an important role in the redox im-
balance in cancer cells [54] and is overexpressed in several human
cancers, including breast carcinomas [55]. Further studies will be
required to determine if Trx play a role in the inhibition of IKKε
expression and/or cell growth induced by Gentian Violet and
Brilliant Green.
The cell growth inhibition observed following treatment of
breast cancer cells with Gentian Violet, Brilliant Green and Tempol
(Fig. 5), was not recapitulated by NOX2 silencing (Fig. 7). This
suggests that inhibition of NOX2-dependent IKKε expression is not
sufﬁcient to mediate the growth inhibiting activities of the com-
pounds. The anti-proliferative action of Gentian Violet and Bril-
liant Green was associated with cleavage of caspase 7 and of the
PARP substrate both in caspase 3-positive ZR75.1 cells and in
caspase 3-deﬁcient MCF-7 cells, suggesting that these compounds
regulate apoptosis of breast cancer cells independently of the
caspase 3 status. However, Tempol displayed distinct responses
depending on the cell line. While in MCF-7 Tempol treatment in-
duced activation of caspase 7, Tempol-induced ZR75.1 cell growth
inhibition was not correlated with caspase activation. The ob-
servation that Tempol induces caspase 7 and downstream PARP
cleavage is in agreement with a previous study reporting that
Tempol induces apoptosis in MCF-7 cells [56]. The absence of
caspase activation and PARP cleavage by Tempol in ZR75.1 cells
implies the activation of a caspase-independent cell growth in-
hibition pathway that remains to be characterized [57]. Further
studies will be required to identify the pathway(s) that is re-
sponsible for the inhibition of cell viability triggered by Gentian
Violet, Brilliant Green and Tempol.
Gentian Violet was recently identiﬁed in a high-throughput
screen aimed at identifying small molecules inhibiting thedegradation of the cyclin-dependent kinase inhibitor p27Kip1,
which is associated with many aggressive phenotypes and a poor
prognosis in various cancers, including breast cancer [58]. Inter-
estingly, transcriptional regulation of p27Kip1 is under the control
of the FOXO3a transcription factors [59], which is a substrate for
IKKε [11]. FOXO3a is inhibited by IKKε-mediated phosphorylation
[11]. Therefore, it is tempting to speculate that Gentian Violet, and
potentially the closely related Brilliant Green, not only inhibit
p27Kip1 degradation, but also increase p27Kip1 transcription as a
result from inhibition of IKKε expression.
Oral use of Tempol has been widely evaluated in a wide range
of animal models [33]. In contrary, the triphenylmethane dyes,
Gentian Violet and Brilliant Green, have been mainly used for to-
pical therapeutic indications [42]. During the course of our work,
Imipramine-blue, a triphenylmethane analog of Gentian Violet,
was created for systemic anti-glioblastoma therapy [60] opening
the path to systemic use of this family of compounds. The ob-
servation that IKKε expression is dependent on NOX2 also points
to the use of a NOX2-speciﬁc inhibitor. The quest for speciﬁc NOX
inhibitors has been underway for more than two decades. The use
of NOX2ds-tat, a peptidic NOX2-speciﬁc inhibitor, yielded very
mild results in our model (data not shown), which might be at-
tributed to a tightly assembled, constitutive NOX2 oxidase [61,62].
We are awaiting availability of small molecule inhibitors with
greater potency to test in this system [63].
Our in vitro data demonstrates that inhibition of NOX2-de-
pendent IKKε expression ranks amongst the pleiotropic activities
of the redox-modulating triphenylmethane dyes, Gentian Violet
and Brilliant Green, and nitroxide Tempol on breast cancer cells.
These ﬁndings provide valuable insights for the development of
novel combined therapies to treat breast tumors highly expressing
Fig. 7. NOX2-dependent regulation of IKKε expression in MCF-7 cells. Total RNA from MCF-7 or ZR75.1 cells (A) or from 10 distinct primary breast tumors (B) was extracted,
subjected to reverse transcription and speciﬁc expression of NOX1-5, DUOX1-2 and actin was evaluated by RT-PCR. Speciﬁc positive controls (Ctrlþ) were used for each gene
as detailed in the methods section. In (C), control (CTRL), NOX2-, NOX5- or IKKε-speciﬁc RNAi were transfected into MCF-7 cells. Efﬁciency of NOX2 and NOX5 silencing was
controlled by RT-qPCR (left panels). IKKε and TBK1 protein expression were analyzed by immunoblot (IB) using speciﬁc antibodies. Actin was used as loading control. IKKε
levels were quantiﬁed by densitometric analysis using the ImageJ software. Quantiﬁcation data are expressed as mean7SEM from nZ3. A t-test was performed to compare
speciﬁc RNAi-transfected to CTRL RNAi-transfected cells. (D) Cell viability was monitored at the indicated times post-RNAi transfection and expressed as % of the corre-
sponding siCTRL-transfected condition at each time point.
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